荟萃分析：肾素-血管紧张素-醛固酮系统阻断剂对Alport综合征患者疗效评估

doi:10.3969/j.issn.1006-298X.2023.05.012

肾脏病与透析肾移植杂志 ›› 2023, Vol. 32 ›› Issue (5): 455-459.DOI: 10.3969/j.issn.1006-298X.2023.05.012

荟萃分析：肾素-血管紧张素-醛固酮系统阻断剂对Alport综合征患者疗效评估

出版日期:2023-10-28 发布日期:2023-10-25

Renin-angiotensin-aldosterone system blockers in patients with Alport syndrome: a report from systematic review and meta-analysis

Online:2023-10-28 Published:2023-10-25

摘要/Abstract

摘要： 尽管肾素-血管紧张素-醛固酮系统（RAAS）阻断剂被认为是Alport综合征（AS）的首要推荐药物已近十年, 但始终缺乏对其全面而系统性的疗效评估。自2020年来，多项队列研究展现了RAAS阻断剂延缓AS患者疾病进展的有利证据。近期发表在《Nephrology Dialysis Transplantation》上的一项系统综述与荟萃分析研究汇总了现有对照研究中的所有可用数据，首次系统性地评估了RAAS 阻断剂治疗AS的长期效果，为指导AS临床实践决策及《Alport综合征诊治专家共识（2023版）》提供了循证依据和数据支持。

关键词: 肾素-血管紧张素-醛固酮系统阻断剂, Alport综合征, 荟萃分析, 队列研究

Abstract: Though renin-angiotensin-aldosterone system (RAAS) blockers have been considered the primary treatment for patients with Alport syndrome (AS) for a decade, there is no comprehensive review with evidencebased analysis evaluating the effectiveness of RAAS blockers in AS. Since 2020, several cohort studies have shown some positive effects of RAAS blockers on improving renal outcomes in patients with AS. A newly published systematic review and meta-analysis summarized all available data from comparative studies and systematically evaluated the effectiveness of RAAS blockers in AS for the first time, which provided data support for improving decisions about the clinical practice of AS.

Key words: renin-angiotensin-aldosterone system blockers, Alport syndrome, meta-analysis, cohort study

曾梦遥, 狄泓伶, 梁菊, 刘志红. 荟萃分析：肾素-血管紧张素-醛固酮系统阻断剂对Alport综合征患者疗效评估[J]. 肾脏病与透析肾移植杂志, 2023, 32(5): 455-459.

ZENG Mengyao, DI Hongling, LIANG Ju, LIU Zhihong. Renin-angiotensin-aldosterone system blockers in patients with Alport syndrome: a report from systematic review and meta-analysis[J]. Chinese Journal of Nephrology, Dialysis & Transplantation, 2023, 32(5): 455-459.

[1]	伍琳琳, 刘栋, 董宁宁等. Alport综合征的药物研发进展[J]. 肾脏病与透析肾移植杂志, 2023, 32(3): 270-275.
[2]	狄泓伶, 刘志红. 血管紧张素转化酶抑制剂／血管紧张素Ⅱ受体拮抗剂治疗Alport综合征的理论及实践[J]. 肾脏病与透析肾移植杂志, 2021, 30(6): 553-558.
[3]	章慧娣，谢静远，陈楠. Ⅳ型胶原相关肾病：从薄基膜肾病、Alport综合征到局灶节段性肾小球硬化[J]. 肾脏病与透析肾移植杂志, 2017, 26(4): 366-369.
[4]	张琰琴，丁方睿，王芳，等. Alport综合征患儿血清可溶性尿激酶型纤溶酶原激活物受体水平变化的临床意义[J]. 肾脏病与透析肾移植杂志, 2016, 25(5): 420-424.
[5]	罗富里\|蔡得汉\|杨林\|等. 血管紧张素转换酶抑制剂/血管紧张素II受体拮抗剂与维持性腹膜透析患者心肾获益的Meta分析[J]. 肾脏病与透析肾移植杂志, 2014, 23(3): 240-246.
[6]	姚小丹, 陈惠萍. 女性Alport综合征[J]. 肾脏病与透析肾移植杂志, 2011, 20(5): 470-474.
[7]	姚小丹,陈欣,黄高渊,等. 他克莫司治疗Alport综合征的近期疗效[J]. 肾脏病与透析肾移植杂志, 2011, 20(4): 338-341.
[8]	黄倩, 曾彩虹, 刘志红. 膜性肾病合并Alport综合征[J]. 肾脏病与透析肾移植杂志, 2011, 20(2): 190-193.

ISSN 1006-298X CN 32-1425/R

荟萃分析：肾素-血管紧张素-醛固酮系统阻断剂对Alport综合征患者疗效评估

Renin-angiotensin-aldosterone system blockers in patients with Alport syndrome: a report from systematic review and meta-analysis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价